Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03110770 · ClinicalTrials.gov registry record · Phase 2
VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 2,428
- Enrollment target
NCT03110770 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 2,428 participants.
The verdict
NCT03110770, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 2,428 participants
- Enrollment target
Study Summary
This was a multicenter, randomized study to evaluate the safety, immunogenicity, and efficacy of VRC-ZKADNA090-00-VP (Zika virus wildtype DNA vaccine) or placebo. In Part A, the primary objective was to evaluate the safety and tolerability of the vaccine in different vaccination regimens. In Part B, the primary objectives were to evaluate the safety and efficacy of the vaccine compared to placebo.
Interventions
- BIOLOGICAL VRC-ZKADNA090-00-VP
- OTHER VRC-PBSPLA043-00-VP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,428 participants |
| Start Date | 2017-03-29 |
| Est. Completion | 2019-10-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03110770
The ClinicalTrials.gov registry entry for NCT03110770 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 2,428 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which VRC-ZKADNA090-00-VP is the first listed.
NCT03110770 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03110770 about?
NCT03110770 is a clinical study titled "VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents". This was a multicenter, randomized study to evaluate the safety, immunogenicity, and efficacy of VRC-ZKADNA090-00-VP (Zika virus wildtype DNA vaccine) or placebo. In Part A, the primary objective was to evaluate the safety and tolerability of the vaccine in different vaccination regimens. In Part B,...
What is the current status of trial NCT03110770?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 2,428 participants. The study started on 2017-03-29. Estimated completion is 2019-10-04.
What interventions are being tested in trial NCT03110770?
The interventions under investigation include: VRC-ZKADNA090-00-VP (BIOLOGICAL), VRC-PBSPLA043-00-VP (OTHER).
Who is sponsoring clinical trial NCT03110770?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.